Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

tockholders' equity:

Preferred stock, $.001 par value,

10,000,000 shares authorized at

September 30, 2008 and December 31, 2007;

no shares issued and outstanding at

September 30, 2008 and December 31, 2007 - -

Common stock, $.001 par value,

100,000,000 shares authorized at

September 30, 2008 and December 31, 2007;

34,423,322 and 26,982,601 shares

issued and outstanding at September 30,

2008 and December 31, 2007, respectively 34 27

Additional paid-in capital 251,375 171,571

Accumulated other comprehensive income 56 220

Deficit accumulated during the

development stage (178,049) (106,935)

Total stockholders' equity 73,416 64,883

Total liabilities and stockholders' equity $105,432 $91,320

Orexigen Therapeutics, Inc.

(a development stage company)

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Period from

September 12,

2002

(Inception)

Three Months Ended Nine Months Ended to

September September September

30, 30, 30,

2008 2007 2008 2007 2008

Revenues:

Collaborative agreem
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed ... Syngenta, are in the process of being consolidated in ... case is In Re: Syngenta AG MIR 162 Corn ... for the District of Kansas. , Management of the ... over to U.S. District Judge John W. Lungstrum.* , ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... that holds much promise for the future of solar ... energy to produce clean and renewable liquid transportation fuels, ... National Laboratory (Berkeley Lab) have reported a technique by ... semiconductor cadmium-selenide was increased 100,000 times. "The key ...
... N.Y., Sept. 11 BioSpecifics Technologies Corp. (Nasdaq: ... products, today announced that BioSpecifics, President, Tom Wegman, will present ... on Wednesday, September 16, 2009, at 9:00 am ET at ... NY. , , A live webcast of ...
... LEUVEN, Belgium, September 11 , ... Year are,Recognised in Nominations , ThromboGenics ... and development of innovative treatments for eye,disease, vascular disease and ... "Biotech Company of the Year" and "Licensing Deal of,the Year" ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 2ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... remember the muscle shirts we wore in our teens and 20s? ... usually is obsolete. Yes, at the big 4-0 we begin to ... it may be gone. It,s an inevitable process of aging called ... A study conducted in mice with accelerated muscle loss at The ...
... 12, 2010) The wait is over for 16-year-old Francesco ... donor heart in a nine-hour transplant operation at Texas Children,s ... first child ever discharged from a pediatric hospital with an ... then, pediatric patients with VADs remained in the hospital, often ...
... have streamlined the process for synthesizing a family of compounds ... and have found that they represent a unique category of ... of the Journal of the American Chemical Society . ... as the kinamycins, which are naturally produced by bacteria during ...
Cached Biology News:Muscle loss finding may one day save physiques 2Texas Children's discharges history-making patient 2Scientists synthesize unique family of anti-cancer compounds 2
... Rack inserts fit into the ... allow you to greatly increase ... deepwell format plates at an ... from the shaker at once ...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
Request Info...
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Biology Products: